The glutamate and dopamine hypotheses are leading theories of the pathoaetiology of
schizophrenia. Both were initially based on indirect evidence from pharmacological studies …

Since the introduction of chlorpromazine and throughout the development of the new-
generation antipsychotic drugs (APDs) beginning with clozapine, the D 2 receptor has been …

Schizophrenia is a serious mental illness with chronic symptoms and significant impairment
in psychosocial functioning. Although novel antipsychotics have been developed, the …

Background: Current antipsychotics have only a limited effect on 2 core aspects of
schizophrenia: negative symptoms and cognitive deficits. Minocycline is a second …

The onset and early course of schizophrenia is associated with subtle loss of grey matter
which may be responsible for the evolution and persistence of symptoms such as apathy …

Major depressive disorder (MDD) is a common, chronic, recurrent mental illness that affects
millions of individuals worldwide. To date, the monoaminergic systems (serotonin …

The pathogenesis of schizophrenia has yet to be fully characterized. Gene–environment
interactions have been found to play a crucial role in the vulnerability to this disease. Among …

Schizophrenia is a complex mental health disorder with positive, negative and cognitive
symptom domains. Approximately one third of patients are resistant to currently available …

Mood disorders are marked by high rates of non-recovery, recurrence, and chronicity, which
are insufficiently addressed by current therapies. Several patho-etiological models have …

Background and purpose Minocycline is a broad‐spectrum antibiotic, effective as a chronic
treatment for recurrent bacterial infections. Beyond its antibiotic action, minocycline also has …